Drug intelligence / Profile preview

AMC6156

Development stage: Phase 2
Lead developer: Animuscure
Modality: Small Molecules
Administration: Oral

Overview

AMC6156 is an investigational small molecule drug developed for the treatment of **sarcopenia** in older adults. Its mechanism of action and molecular target are undisclosed in public sources, but it is undergoing Phase 2 clinical trials to assess its efficacy in improving physical function, muscle mass, and strength in elderly patients with sarcopenia. The drug is administered orally, and clinical trials are evaluating various dosages over a 12-week period with endpoints including improvements in the Short Physical Performance Battery (SPPB), muscle mass, grip strength, and quality of life.

Targets

PPAR (PPAR family)CDO1 (Cysteine dioxygenase type 1)

Beyond the preview

Go deeper on AMC6156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMC6156.

Explore the full profile